GlassScriptPhysician profile
Amer Kadri
NPI 1285076828
$41,807.90
in general payments reported to CMS, 2019-2025
33 companies · $1,637 in 2025
The $1,637 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $621 · 2020: $442 · 2021: $660 · 2022: $1,180 · 2023: $25K · 2024: $12K · 2025: $1,637.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Grant: $29K · Travel and Lodging: $5,009 · Food and Beverage: $4,586 · Education: $684.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Grant | $28,624.96 |
| Travel and Lodging | $5,009.22 |
| Food and Beverage | $4,586.05 |
| Education | $684.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $15,814.15 | 2023-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Pascal, Sapien 3 Ultra Resilia |
| Medtronic, INC. | $13,059.18 | 2023-2025 | Corevalve Evolut R, Symplicity G3 |
| Abbott Laboratories | $7,692.96 | 2020-2024 | Ensite, Mitraclip, Optis |
| W. L. Gore & Associates, INC. | $1,637.72 | 2023-2025 | Gore Cardioform Septal Occluder, Gore Cardioform Asd Occluder |
| Amgen INC. | $735.25 | 2019-2024 | Repatha |
| Abiomed | $376.98 | 2022-2025 | Impella |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $337.94 | 2019-2025 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $328.02 | 2019-2024 | Farxiga |
| Philips North America LLC | $261.02 | 2021-2025 | Igt Devices Undivided, Azurion 7 M20 |
| Boston Scientific Corporation | $225.14 | 2021-2025 | Watchman Flx |
| Pfizer INC. | $224.68 | 2021-2025 | |
| Astellas Pharma US INC | $198.00 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $125.00 | 2022 | |
| Novartis Pharmaceuticals Corporation | $104.79 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $93.14 | 2023-2025 | Camzyos, Eliquis |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kestra Medical Technology Services, INC. | $89.55 | 2025 | Assure Wcd |
| Actelion Pharmaceuticals US, INC. | $88.97 | 2022-2025 | Opsumit, Uptravi |
| Recor Medical INC | $68.70 | 2024-2025 | Paradise Ultrasound Renal Denervation System, Paradise Renal Denervation System |
| Cardiovascular Systems INC. | $39.86 | 2020-2023 | Diamondback Coronary |
| Angiodynamics, INC. | $38.83 | 2024 | Alphavac |
| Baxter Healthcare | $31.92 | 2025 | Hillrom - Cardiac Ambulatory Monitor |
| Teleflex LLC | $30.09 | 2023 | Manta |
| Siemens Medical Solutions USA, INC. | $23.68 | 2024 | Acuson Origin Diagnostic Ultrasound System |
| United Therapeutics Corporation | $21.63 | 2025 | Tyvaso |
| Heartflow, INC. | $21.09 | 2025 | |
| Bridgebio Pharma, INC. | $20.86 | 2025 | Attruby |
| Cordis US Corp. | $20.69 | 2025 | Mynx Control Venous |
| Terumo Medical Corporation | $18.42 | 2024 | Tr Band, Angio-Seal |
| Biotronik INC. | $17.66 | 2025 | |
| Merck Sharp & Dohme LLC | $16.73 | 2025 | Verquvo |
| Bard Peripheral Vascular, INC. | $16.22 | 2023 | |
| Chiesi USA, INC. | $15.07 | 2022 | |
| Amarin Pharma, INC. | $13.96 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$140.70 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amer Kadri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.